Dianthus Therapeutics, Inc.
DNTHHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Dianthus Therapeutics, Inc. focuses on Biotechnology services and products. Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. The $4.97B market capitalization puts DNTH squarely in mid-cap range for its industry. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Market Cap
$4.97B
Beta
0.09
P/E (TTM)
—
P/E (Fwd)
-19.54
EPS (TTM)
$-4.23
EPS (Fwd)
$-4.65
ROE
-22.7%
ROA
-15.0%
Cash
$1.11B
Total Debt
$1.4M
Free CF
-$71.0M
52W Change
422.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $1.11B in cash comfortably exceeding the $1.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$71.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -22.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $6.4M (2022) to $2.0M (2025), a 68% decline worth watching.
DNTH's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, DNTH has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing DNTH's risk profile alongside its fundamentals and technical indicators provides a more complete picture.